Bombesin receptor subtype 3 (BRS-3) is an orphan G protein-coupled receptor. Based on the obese phenotype of male BRS-3-deficient mice, BRS-3 has been considered an attractive target for obesity treatment. Here, we developed a selective BRS-3 agonist (compound-A) and evaluated its antiobesity effects. Compound-A showed anorectic effects and enhanced energy expenditure in dietinduced-obese (DIO)-F344 rats. Moreover, repeated oral administration of compound-A for 7 days resulted in a significant body weight reduction in DIO-F344 rats. We also evaluated compound-A for cardiovascular side effects using telemeterized Sprague-Dawley (SD) rats. Oral administration of compound-A resulted in transient blood pressure increases in SD rats. To investigate the underlying mechanisms of BRS-3 agonist effects, we focused on the suprachiasmatic nucleus (SCN), the main control center of circadian rhythms in the hypothalamus, also regulating sympathetic nervous system. Compound-A significantly increased the messenger RNA expression of Brs-3, c-fos, and circadian rhythm genes in SCN of DIO-F344 rats. Because SCN also controls the hypothalamicpituitary-adrenal (HPA) axis, we evaluated the relationship between BRS-3 and the HPA axis. Oral administration of compound-A caused a significant increase of plasma corticosterone levels in DIO-F344 rats. On this basis, energy expenditure enhancement by compound-A may be due to a circadian rhythm change in central and peripheral tissues, enhancement of peripheral lipid metabolism, and stimulation of the sympathetic nervous system. Furthermore, the blood pressure increase by compound-A could be associated with sympathetic nervous system stimulation via SCN and elevation of plasma corticosterone levels through activation of the HPA axis.
O besity has become a serious social problem because it contributes to the development of metabolic diseases (diabetes mellitus, hypertension, and dyslipidemia) and certain types of cancer (1, 2) . The rate of obesity, especially morbid obesity, is dramatically increasing throughout the world, which has resulted in serious public health issues (3, 4) . Lifestyle interventions, including diet and exercise, are the first line of obesity management but do not sufficiently control and support sustainable weight loss, indicating that other strategies, such as bariatric surgery and/or pharmacotherapy, are required (5) . As one of the drug discovery strategies for obesity, pharmacologic therapy, which reduces hyperplasia and enhances energy expenditure, thereby mimicking exercise, would be ideal. The US Food and Drug Administration has recently approved several new antiobesity drugs (lorcaserin, phentermine-topiramate, bupropionnaltrexone, and liraglutide), but they have not fully met patients' needs for antiobesity treatment because of insufficient efficacy, high costs, and safety concerns (2) (3) (4) (5) (6) .
In modern societies, physiologic circadian oscillation is impaired as a result of shift work, nocturnal social activities, jet lag, and other factors. It has been well described that disorders of circadian rhythm promote systemic metabolic dysfunction associated with obesity or diabetes in both humans and rodents (7) . In a cohort study of the difference between sleep timing and the duration of so-called social jet lag, social jet lag was significantly associated with phenotypes of overweight and metabolic dysfunction (8) . Thus, circadian rhythm changes are considered to correlate with obesity. The circadian rhythm system consists of central and peripheral components (9) . The central component is located in the suprachiasmatic nucleus (SCN) of the hypothalamus and acts as a master circadian rhythm regulator under a strong influence of the light/dark input from the eyes. The activity of the peripheral circadian rhythm is synchronized to that of the central master circadian rhythm through both humoral and neural connections (10) . Neurons of the central circadian rhythm in SCN send efferent projections to other parts of the brain, such as the paraventricular nucleus (PVN), medial preoptic area (MPA), dorsomedial hypothalamic nucleus (DMH), and the pineal gland, to transfer the timing information and to regulate the secretion of pituitary hormones and melatonin, as well as to control sleep, food intake, glucocorticoid secretion, body temperature, and blood pressure (10) (11) (12) (13) . PVN, regulated by SCN, also coordinates the hypothalamic-pituitaryadrenal (HPA) axis, a neuroendocrine system that regulates the circulating levels of vital glucocorticoid hormones, which, in turn, have important regulatory effects on the cardiovascular, metabolic, cognitive, and immunologic state of the animal (14) (15) (16) . It has been reported that glucocorticoids affect the blood pressure through direct action on endothelial cells via endothelial nitric oxide synthase inhibition and sodium accumulation in blood (17) . Glucocorticoids affect the peripheral circadian rhythm in almost all organs and tissues. Glucocorticoids reset their circadian rhythm by phase-shifting the expression of several clockrelated genes in peripheral organs, including the liver, kidney, and heart (18) , and also by influencing the expression of several clock-related genes in peripheral tissues and some brain areas (18) (19) (20) .
The bombesin receptor subtype 3 (BRS-3) is a member of the bombesin receptor subfamily of G protein-coupled receptors, which also includes the neuromedin B-releasing peptide receptors (NMBR, or BRS-1) and gastrin-releasing peptide receptors (GRPR, or BRS-2) and has 47% to 52% homology with the GRPR and NMBR (21) . BRS-3 does not show affinity to any known bombesin-related peptide, and its natural ligand is still unknown (22, 23) . Although the physiologic function of BRS-3 remains unclear, male BRS-3-deficient (Brs-3
2/Y
) mice develop obesity and exhibit a reduced metabolic rate and increased food intake (24) (25) (26) (27) . These results suggest that BRS-3 might be an attractive target for the treatment of obesity. Recently, an orally available, selective, small-molecule BRS-3 agonist, MK-5046, has been developed and shown to reduce the food intake and body weight and increase the energy expenditure in animals. MK-5046 also caused side effects, such as transient increases of the body temperature, heart rate, and blood pressure in animals (28) . In addition, MK-5046 also raised blood pressure in humans in a clinical trial (29) .
Although the cardiovascular adverse effects and energy expenditure enhancement by the BRS-3 agonist were reported to be associated with the activation of the sympathetic nervous system (30), the precise mechanisms remain unknown. BRS-3 is predominantly expressed in some specific hypothalamus regions related to the control of energy homeostasis (23, 31, 32) . In addition, BRS-3 is also expressed in SCN, and its expression is affected by light exposure (33, 34) . Thus, BRS-3 might be associated with circadian rhythms. Ladenheim et al. (26) reported that plasma corticosterone levels were increased by food restriction in wild-type mice but were not elevated in Brs-3 2/Y mice. Thus, it was speculated that BRS-3 might also be associated with the HPA axis.
In this study, we developed an orally available, selective, small-molecule BRS-3 agonist, compound-A, and assessed its pharmacologic effects on obese rats. We then explored potential mechanisms underlying the BRS-3 agonist-induced energy expenditure and blood pressure regulation, focusing on BRS-3 expression in SCN and on the regulation of sympathetic nervous system using compound-A as a tool compound.
Materials and Methods

Compounds
Compound-A, compound-B (the distomer of compound-A), and compound-C (racemate) were synthesized at Takeda Pharmaceutical Company Ltd. (Kanagawa, Japan). In detail, 5-benzyl-N-tert-butyl-8-methoxy-6-oxo-5, 6-dihydro-4H-thieno [2, 3-d] [2] benzazepine-4-carboxamide [Ca aequorin assay BRS-3 human/rat: half maximal effective concentration (EC 50 ), 1800 and 300 nM, respectively] was chosen as an initial hit compound from a high-throughput screening of the in-house compound library. To potentiate the in vitro BRS-3 agonistic activity and improve pharmacokinetic profiles, we started an initial study of the structure-activity relationship and then focused on an optimization study. As a result, we discovered a dibenzo [c, e] azepine derivative compound-C (the racemate of compound-A and compound-B) (6-benzyl-N-tert-butyl-9-methoxy-7-oxo-6,7-dihydro-5H-dibenzo[c,e]azepine-5-carboxamide, Ca aequorin assay BRS-3 human/rat: EC 50 , 270/130 nM) and the corresponding eutomer compound-A (Ca aequorin assay BRS-3 human/rat: EC 50 , 250/100 nM) as a selective BRS-3 agonist.
Sibutramine was synthesized by Alexis Biochemicals (Lausen, Switzerland). Sibutramine, a serotonin-norepinephrine reuptake inhibitor, induces weight loss by enhancing satiety and increases blood pressure through its norepinephrine effect in human and rodents (35) . Therefore, we used sibutramine as a positive control for experiments on anorectic effect, antiobese effect, and cardiovascular effect.
CL316,243 was purchased from Tocris Bioscience (Minneapolis, MN). Although sibutramine did not increase metabolic rate in mice, a b3 adrenoreceptor-selective agonist persistently increased it (36) . It was also reported that CL316,243 did not reach the brain because of the impermeability of the blood-brain barrier (37) . Thus, we used CL316,243 as a positive control for measurement of metabolic rate. To find difference of gene expression patterns between central nervous system-derived metabolic rate increase and peripheral tissue-derived metabolic rate elevation, we used CL316,243 for analysis of peripheral gene expressions. Compounds were suspended in a 0.5% methylcellulose (MC) solution for oral dosing. The profiles of compound-A, compound-B, and compound-C are shown in Fig. 1 .
BRS-1, -2, and -3 agonism assays and pharmacokinetic analysis using mouse and rat cassette dosing For the functional assays, agonist-induced mobilization of intracellular Ca 2+ was measured by an aequorin bioluminescence assay in CHO-K1 cells overexpressing BRS-3. The potencies for BRS-1 and BRS-2 were measured by a FLIPR assay (Molecular Devices, Sunnyvale, CA) with a Calcium 6 kit using CHO-K1 cells transiently expressing BRS-1 and BRS-2. For human BRS-3 membrane-binding assay, against BRS-3 peptidic agonist, bombesin (6) (7) (8) (9) (10) (11) (12) (13) (14) , (D-[ 125 I]Tyr 6 , b-Ala 11 , Phe 13 , Nle 14 ) (NEX-377; Perkin Elmer Japan, Tokyo, Japan) was used (38) . Binding assay was performed in a manner similar to that described previously (27) using membranes prepared from CHO-K1 cells overexpressing human BRS-3. Male 8-week-old Institute of Cancer Research (ICR) mice (n = 3) and male 8-week-old Crl: CD(SD)(IGS) rats (n = 3) were administered compound-A orally (1 mg/kg/5 mL, suspended in 0.5% MC aqueous solution) using cassette dosing. After administration, blood samples were collected and centrifuged to obtain a plasma fraction. The plasma samples were deproteinized by mixing with acetonitrile, followed by centrifugation. Compound concentrations in the supernatant were measured by liquid chromatography-tandem mass spectrometry.
Animals
F344/Jcl rats (male, 5-week-old) were purchased from CLEA Japan (Shizuoka, Japan) and were fed a high-fat diet (HFD: D12451; Research Diets, New Brunswick, NJ) to develop diet-induced obesity. BRS-3-deficient (Brs3 2/Y ) mice were purchased from Taconic (Germantown, NY) and backcrossed for at least eight generations onto a C57BL/6 background. All animals were kept at an appropriate temperature (23-25°C) and 12-hour light/dark cycle (7:00-19:00 for rats, 7:30-19:30 for Brs-3 2/Y mice). All animal experiments were performed in compliance with the guidelines for the care and use of Figure 1 . BRS-1, -2, and -3 agonism assays and pharmacokinetic (PK) analysis using mouse and rat cassette dosing. For the functional assays, agonist-induced mobilization of intracellular Ca 2+ was measured by an aequorin bioluminescence assay in CHO cells overexpressing BRS-3. The potencies for BRS-1 and BRS-2 were measured by a FLIPR assay with a calcium 6 kit using CHO cells transiently expressing BRS-1 and BRS-2. The half maximal inhibitory concentration (IC 50 ) value for human BRS-3 was calculated from the results of binding assay using membranes prepared from HEK293 cells overexpressing BRS-3. Male 8-week-old Institute of Cancer Research (ICR) mice (n = 3) and male 8-week-old Crl:CD(SD)(IGS) rats (n = 3) were administered orally with compound-A (1 mg/kg/5 mL, suspended in 0.5% MC aqueous solution) using cassette dosing. After administration, blood samples were collected and centrifuged to obtain a plasma fraction. The plasma samples were deproteinized by mixing with acetonitrile, followed by centrifugation. Compound concentrations in the supernatant were measured by liquid chromatography-tandem mass spectrometry. AUC, area under the curve; Tmax, time at which the maximum plasma concentration was reached.
laboratory animals, and all animal protocols were reviewed and approved by the Institutional Animal Care and Use Committee/ Ethics Committee of Takeda Pharmaceutical Company Ltd.
Quantitative reverse transcriptase polymerase chain reaction
Total RNA was isolated from central and peripheral tissues using the RNeasy mini kit (Qiagen, Hilden, Germany). Complementary DNA (cDNA) was synthesized from total RNA using a high-capacity cDNA reverse transcription kit (Applied Biosystems, Carlsbad, CA) to be used for real-time quantitative polymerase chain reaction (PCR) analysis. For quantification of gene expression, the following sets of predesigned primers and probes for each gene (Applied Biosystems) were used: rat clock, Rn00573120_m1; rat c-fos, Rn01757240_m1; rat period circadian protein homolog 1 (Per1), Rn01325256_m1; rat Per2, Rn01427704_m1; rat peroxisome proliferator-activated receptor a(PPARa), Rn00566193_m1; rat hormone-sensitive lipase (Hsl), Rn00563444_m1; rat Brs-3, Rn00569103_m1; rat adipose triglyceride lipase (Atgl), Rn01479969_m1; rat mitochondrial uncoupling protein 2 (Ucp2), Rn01754856_m1; rat Ucp3, Rn00565874_m1; rat peroxisomal acyl-coenzyme A oxidase (Aco), Rn01460628_m1; rat peroxisome proliferator-activated receptor gcoactivator 1 a (Pgc-1a), Rn 00580241_m1; rat cryptochrome circadian clock 1 (Cry1), Rn01503058_g1; and rat glyceraldehyde-3-phosphate dehydrogenase (Gapdh), Rn01775763_g1, and rat cyclophilin, Rn00452692_m1. Messenger RNA (mRNA) expression levels were quantified by using an ABI Prism 7900 PCR system (Applied Biosystems). The relative amount of each transcript was normalized to the amount of rat cyclophilin or Gapdh mRNA.
Effects of compound-A on body weight and food intake in Brs-3 2/Y mice Male Brs-3 2/Y mice (5-week-old) and age-matched male wild-type mice were individually housed and fed a regular chow (CE-2, CLEA Japan). From the age of 6 weeks, they were fed HFD (D12451) for 29 weeks and were acclimated to oral dosing for 1 week. The mice were divided into four groups based on the nocturnal food intake on the previous day and body weight in the morning of the day of drug administration. The animals were administered orally with the vehicle (0.5% MC solution), compound-A (30 and 100 mg/kg), or sibutramine (10 mg/kg). Food intake and body weight were measured 16 hours and 24 hours after drug administration.
Antiobesity effects of compound-A in DIO-F344 rats
DIO-F344 rats (male, 54-week-old) were fed with a powdery HFD (D12451M) from 8 weeks of age and were acclimated to oral dosing for 7 days. The rats were divided into five groups (n = 6 each) based on the body weight and nocturnal food intake on the day before the starting day. The rats were administered orally with the vehicle (0.5% MC solution), compound-A (3, 10, and 30 mg/ kg), or sibutramine (1 mg/kg) from 1 to 2 hours before the onset of the dark phase for 7 days. Body weight was measured daily before drug administration (at 16:00 to 18:00). Food intake was measured at 1, 2, 5, 6, and 7 days after the dosing (at 16:00 to 18:00).
Enhancement of energy expenditure by compound-A and compound-B in DIO-F344 rats
DIO-F344 rats (male, 45-week-old) were acclimated to oral dosing for 1 week. At 8:00 AM on the day of this study, they were housed individually in the metabolic chamber of an Oxymax system (Columbus Instructions, Columbus, OH) for acclimation to the chamber. The rats were divided into five groups (vehicle, n = 3; compound-A [3 mg/kg, n = 4; 10 mg/kg, n = 4; 30 mg/kg, n = 4] and CL316,243, 2 mg/kg, n = 1) based on the body weight and energy expenditure measured around 10 AM for 1 hour. At approximately 11:00 AM, the rats were administered orally with the vehicle (0.5% MC solution), compound-A (3, 10, and 30 mg/kg), or CL316,243 (2 mg/kg), and their metabolic rate and respiratory quotient (RQ) were measured for 5 hours. For the assessment of compound-B, at 8:00 AM on the day of this study, DIO-F344 rats (male, 52-week-old) were acclimated to individual housing in the metabolic chamber of the Oxymax system. The rats were divided into four groups (n = 4 each) based on the same indices as mentioned earlier. At approximately 11 AM, the rats were administered orally with the vehicle (0.5% MC solution), compound-B (30 and 100 mg/kg), or CL316,243 (2 mg/kg), and their metabolic rate and RQ were measured for 5 hours. To quantify the effect of the drugs on the resting metabolic rate, the data were expressed as the mean of the area under the curve of metabolic rate for 5 hours after dosing.
Effects of compound-A on blood pressure and heart rate in telemeterized Sprague-Dawley rats Male Sprague-Dawley (SD) rats (5-week-old) were purchased from CLEA Japan. In a week, they were implanted with telemetry transmitters (PA-C20; Data Sciences International, St. Paul, MN) in the abdominal aorta according to the manual. The transmitter portion of the device was positioned inside the intraperitoneal cavity. After 4 weeks, the rats were orally dosed with water for 7 days for acclimation. Then, at 11 weeks of age, the rats were orally dosed with the vehicle (0.5% MC, n = 5), compound-A (100 mg/kg, n = 5), and sibutramine (10 mg/kg, n = 4-5) at approximately 10:00 AM. The mean blood pressure and heart rate were monitored for 5 hours after administration.
Effects of compound-A on gene expression in hypothalamus of DIO-F344 rats
To analyze the gene expression change in the hypothalamus, DIO-F344 rats (male, 53-week-old) were orally administered the vehicle (0.5% MC solution) and compound-A (30 mg/kg) at 9:00 AM after 16 hours of fasting or after having been fed ad libitum. At 1 hour after the dosing, the rats were deeply anesthetized, and some hypothalamus regions, such as the SCN, PVN, and the arcuate nucleus (ARC), as well as the nucleus of the solitary tract (NTS), were dissected. Total RNA was isolated from these tissues, and cDNA was synthesized as described previously. Then, quantitative reverse transcriptase PCR was performed. mRNA expression of each gene was normalized to that of rat cyclophilin.
Effects of compound-A on gene expression in the liver, white adipose tissue, and skeletal muscles of DIO-F344 rats For the evaluation of gene expression changes in the liver, white adipose tissue (WAT), and skeletal muscles (SKM), DIO-F344 rats (male, 60-week-old) were orally administered the vehicle (0.5% MC solution), compound-A (30 mg/kg), or CL316,243 (2 mg/kg) at 9:00 AM after 16 hours of fasting or after having been fed ad libitum. To avoid the effect of food, the compounds were administered in a fasted state. At 1 hour after the dosing, the rats were euthanized, and the liver and epididymal and mesenteric WAT and SKM were dissected. Total RNA was isolated from these tissues, and cDNA was synthesized as described earlier. Then, quantitative reverse transcriptase PCR was performed. mRNA expression of each gene was normalized to that of rat cyclophilin.
Plasma parameters and corticosterone levels DIO-F344 rats (male, 65-week-old) were orally administered the vehicle (0.5% MC solution) and compound-A (30 mg/kg) at 9:00 AM after 16 hours of fasting. At 1, 2, and 4 hours after dosing, blood samples were collected from the tail vein and centrifuged at 12,000 rpm for 5 minutes. Plasma glucose, triglycerides, and nonesterified fatty acids were measured by using auto analyzer system 7180 (Hitachi, Tokyo, Japan). Plasma corticosterone levels were measured by using an enzyme-linked immunosorbent assay kit (Assaypro, St. Charles, MO).
Statistical analysis
Data are expressed as the mean 6 standard deviation. Data involving more than two groups was assessed by the Williams test or one-way analysis of variance, followed by the Tukey multiple comparisons test. Differences between two groups were assessed using the Student t test or Aspin-Welch t test, followed by Bonferroni's correction for comparing multiple time points vs the control group.
A P value ,0.025 for the Williams test and ,0.05 for the Tukey multiple comparison test and Student t test or Aspin-Welch t test were considered to represent a statistically significant difference (EXSUS version 8.0; CAC ExiCARE, Osaka, Japan).
Results
Profiles of BRS-3 agonist compounds
The structures of compound-A and compound-B (Ror S-6-benzyl-N-tert-butyl-9-methoxy-7-oxo-6,7-dihydro-5H-dibenzo[c,e]azepine-5-carboxamide) are presented in Fig. 1 . Compound-A and compound-B are chiral compounds that were separated with Chiralpak IC (Daicel) using hexane-ethanol as an eluent; each absolute configuration was not determined. Compound-A (more polar) was identified as the active conformer (eutomer), with an EC 50 value of 100 nM in an aequorin assay (Ca 2+ ) against the rat BRS-3. Compound-B (less polar) was identified as the distomer and did not show agonistic action at 10 mM on the rat BRS-3. The half maximal inhibitory concentration value of compound-A on human BRS-3 was 300 nM. To evaluate the interaction with other receptors and channels, we used the assay service of Eurofins Panlabs, Inc. (St. Charles, MO). The results for compound-A at 10 mM are shown in Supplemental Table 1 . Compound-A at 10 mM had no significant inhibitory effect on them. To determine the pharmacokinetic profile of compound-A, ICR mice and SD rats were orally administrated 1 mg/kg of compound-A, and blood samples were collected. The compound concentrations were measured by liquid chromatography-tandem mass spectrometry. The maximum plasma concentration (C max ), time at which the C max was reached, and bioavailability were 69.1 ng/mL, 0.5 hours, and 21.7% in rats and 78.8 ng/mL, 0.3 hours, and 13.2% in mice, respectively. Moreover, other compound profiles of compound-A, such as LogD, cLogP, CYPs inhibition, metabolic stability rate, and permeability on the parallel artificial membrane permeability assay were measured (39) and are shown in Supplemental Table 2 . Table 3 . These results indicated that the anorectic effect of compound-A is BRS3 dependent.
Antiobesity effects of compound-A in DIO-F344 rats
To evaluate the antiobesity effect of compound-A, we repeatedly administered compound-A (3, 10, and 30 mg/kg) to DIO-F344 rats and measured their food intake and body weight. The repeated oral administration of compound-A (30 mg/kg) significantly decreased body weight [ Fig. 3(a) and 3(c) ], and this was accompanied by a significant food intake reduction [ Fig. 3(b)  and 3(d) ]. Repeated oral administration of sibutramine (1 mg/kg) also significantly decreased body weight and cumulative food intake in DIO-F344 rats. The raw data from these experiments are shown in Supplemental Table 4 .
Enhancement of energy expenditure by compound-A in DIO-F344 rats
We analyzed the effects of a single administration of compound-A on energy expenditure in DIO-F344 rats. A single oral administration of compound-A (3, 10, and 30 mg/kg) significantly increased the metabolic rate and decreased RQ in a dose-dependent manner [ Fig. 4(a)-4(c)] . A b3-adrenoceptor agonist, CL316,243 (2 mg/kg), also increased the metabolic rate and decreased RQ. A single oral administration of compound-B (30 and 100 mg/kg) did not change the metabolic rate or RQ [ Fig. 4(d)-4(f) ].
Effects of compound-A on heart rate and blood pressure in telemeterized SD rats Previous studies have shown that the BRS-3 agonist MK-5046 (3 mg/kg) caused a transient increase of blood pressure and heart rate in telemeterized SD rats (28) . We also evaluated the effect of compound-A on the blood pressure and heart rate change in telemeterized SD rats, considering that the EC 50 values of MK-5046 were 14, 2.2, and 21 nM for the human, rat, and mouse BRS-3, respectively (28) . The EC 50 values of compound-A were 250 and 100 nM for the human and rat BRS-3, respectively (Fig. 1) . On the basis of the compound-A EC 50 and pharmacokinetics (PK) data, we used 100 mg/kg of compound-A for this evaluation. Moreover, we performed a PK study after oral dosing of compound-A in both SD rats and DIO-F344 rats; these PK data are shown in Supplemental Fig. 1 . Plasma C max values after oral administration at 10 and 30 mg/kg in DIO-F344 rats were 0.56 and 1.01 mg/mL, respectively. Plasma C max after oral administration at 100 mg/kg in SD rats was 0.72 mg/mL. According to these PK data, we used a dose of 100 mg/kg for the telemetry study in SD rats. Compound-A (100 mg/kg) transiently increased blood pressure at 70 and 80 minutes after dosing [ Fig. 5(a) ]. These effects were eliminated at 5 hours after dosing. In contrast, sibutramine showed a persistent and significant increase of blood pressure after the dosing, and the heart rate also strongly increased during this experiment [ Fig. 5(a) and (b) ].
Effects of compound-A on gene expression in hypothalamus of DIO-F344 rats
We tried to explore the mechanisms of the BRS-3 agonist action on the blood pressure increase by focusing on SCN. First, we measured the Brs-3 mRNA Moreover, compound-A also increased the c-fos mRNA expression in other hypothalamus regions, such as PVN, ARC, and NTS. These results suggested that compound-A stimulated these regions. In this study, although we used the data from the fasted state to mitigate the individual differences in food intake timing for evaluation of the effect of compound-A on gene expressions, we also found similar data on gene expression change in the brain at the fed state (Supplemental Fig. 2 ).
Effects of compound-A on HPA axis in DIO-F344 rats
In this study, we confirmed that compound-A could change the circadian gene expression in SCN and tended to activate the c-fos mRNA expression in PVN. PVN receives circadian rhythms from SCN and coordinates the glucocorticoid secretion via the HPA axis. Thus, we next focused on the effects of the BRS-3 agonist on the HPA axis. We measured plasma parameters, such as plasma glucose, triglycerides, and free fatty acid, for 4 hours and corticosterone levels in DIO-F344 rats after a single treatment with compound-A (30 mg/kg) for 2 hours. Compound-A slightly increased plasma glucose and free fatty acid levels and decreased triglyceride levels [ cumulative food intake were calculated. The data are expressed as the mean 6 standard deviation for six animals. The statistical significance was determined by using (d) raw data and (a-c) normalized data. #P , 0.025 vs vehicle by the one-tailed Williams test followed by Bonferroni correction for comparing multiple time point vs the control group; *P , 0.05 vs vehicle by the Student t test or Aspin-Welch t test followed by Bonferroni correction for comparing multiple time point vs the control group.
7(a)-7(f)]. Moreover, compound-A significantly increased the plasma corticosterone level at 1 hour after dosing. These results seemed to indicate the stimulation of the HPA axis or sympathetic nervous system by compound-A.
Effects of compound-A on gene expression in peripheral tissues of DIO-F344 rats
We evaluated the effect of compound-A on peripheral circadian rhythm-related gene expression in DIO-F344 rats using CL316,243 as a positive control for energy expenditure. Both compound-A (30 mg/kg) and the b3-adrenergic receptor agonist CL316,243 (2 mg/kg) significantly increased the energy expenditure and reduced RQ, which indicated that fatty acid consumption was elevated [ Fig. 4(c) and 4(f) ]. Thus, we measured peripheral circadian rhythm-related gene expression as described previously and found that the expression of the genes correlated with fatty acid metabolism in the liver, WAT, and SKM of DIO-F344 rats. Under fasting conditions, most fatty acid metabolism-related genes, such as PPARa, Pgc-1a, Aco, and Ucp2, were suppressed in the Figure 4 . Effect of a single oral administration of compound-A and compound-B on energy expenditure in DIO-F344 rats. A time course of the metabolic rate was monitored continuously for 5 hours by using an Oxymax system. DIO-F344 rats were treated orally with vehicle (V; 0.5% MC solution, n = 3), compound-A (3, 10, and 30 mg/kg, n = 4 each), or CL316,243 (2 mg/kg, n = 1), and the (a) metabolic rate, (b) cumulative metabolic rate for 5 hours after dosing, and (c) RQ were measured. In addition, DIO-F344 rats were treated orally with vehicle (0.5% MC solution, n = 4), compound-B (30 and 100 mg/kg, n = 4), or CL316,243 (2 mg/kg, n = 4), and the (d) metabolic rate, (e) cumulative metabolic rate for 5 hours after dosing, and (f) RQ were measured. The data are expressed as the mean 6 standard deviation. #P , 0.025 vs vehicle by the one-tailed Williams test followed by Bonferroni correction for comparing multiple time point vs the control group; *P , 0.05 vs vehicle by the Student t test or Aspin-Welch t test followed by Bonferroni correction for comparing multiple time point vs the control group. doi: 10.1210/en.2016-1825 https://academic.oup.com/endoliver and SKM (Figs. 8 and 9 ). Although both compound-A and CL316,243 produced a significant increase in energy expenditure in DIO-F344 rats, there were almost no changes in the expression of fatty acid metabolismrelated genes, such as Aco, Pgc-1a, Ucp2, Ucp3, and Atgl, in these tissues (Figs. 8-10 
Discussion
In this study, we developed a BRS-3 agonist, compound-A, that reduced food intake and body weight, with an increase of energy expenditure, in DIO-F344 rats. Repeated administration of compound-A (30 mg/kg) significantly reduced the body weight of DIO-F344 rats. Because the potency of compound-A for BRS-3 (250 and 100 nM for human and rat BRS-3, respectively) was weaker than that of MK-5046 (14, 2.2, and 21 nM for human, rat, and mouse BRS-3, respectively), a high dose (30 mg/kg) of compound-A was needed for body weight reduction in DIO-F344 rats.
Compound-B, the distomer of compound-A, did not increase energy expenditure at doses below 100 mg/kg and did not activate human and rat BRS-3 in vitro up to a concentration of 10 mM (Fig. 1) . Although we did not have the PK data for compound-B, we speculated that enhancement of the metabolic rate by compound-A would be related to its BRS-3 agonist action, as compared with that of compound-B, because we have confirmed by using Brs-3 -/Y mice that the anorectic effect of compound-A is BRS-3-dependent (Fig. 2) . In this study, we showed the selectivity of Compound-A between BRS subtypes, such as GRPR and NMBR (BRS-1 and BRS-2), and also showed its selectivity for BRS-3 by using BRS-3 deficient mice. In addition, we evaluated the interaction of compound-A with some receptors, channels, and enzymes (Supplemental Table 1 ). There were no significant inhibitory effects on them by compound-A at 10 mM.
A previous study has reported that MK-5046 increased blood pressure through stimulation of the sympathetic nervous system (30) . Thus, we evaluated the blood pressure changes by compound-A and sibutramine treatments by using telemeterized SD rats. Similar to the previous study, compound-A also transiently increased blood pressure in rats. Although the blood pressure and heart rate increases were transient and much weaker than Figure 5 . Effects of compound-A on (a) blood pressure and (b) heart rate in telemeterized SD rats. Male rats (CE-2, CLEA Japan) were implanted with telemetry transmitters. After 1 week of acclimation, the animals were dosed with the vehicle (0.5% MC; s, n = 5), compound-A (100 mg/kg; ■ , n = 5), or sibutramine (10 mg/kg; :, n = 4 to 5). The data are expressed as the mean 6 standard deviation. *P , 0.05 vs vehicle by the Student t test or Aspin-Welch t test followed by Bonferroni correction for comparing multiple time points vs the control group.
those caused by sibutramine treatment, these side effects were considered to be on-target effects. The precise mechanisms of the blood pressure increase by BRS-3 agonists remain unknown.
According to a previous study on a tissue distribution of Brs-3 mRNA in rats, the highest expression was observed in the hypothalamus, where the BRS-3 protein was highly expressed in ARC and PVN (31, 32) . Compound-A significantly or slightly increased c-fos mRNA expression in ARC and PVN at fasted and fed states. Because BRS-3 agonist has been shown in this and other studies to decrease food intake, this activation may be an effect of energy regulatory pathways within these brain regions and not due to downstream activation from SCN. Previous studies have also shown that BRS-3 is expressed in SCN of the hypothalamus, and its expression is affected by light exposure (33, 34) . In mammals, SCN is the center of circadian rhythm clock genes and is linked to peripheral tissues via the sympathetic nervous system (40) . Food intake, hormonal synthesis and release, endogenous regulation of thrombolysis, body temperature maintenance, blood pressure, and aspects of metabolism are among the rhythmic physiologic processes influenced by circadian rhythm clock genes (41) . SCN is the origin for sympathetic nervous system; stimulates the sympathetic nervous system via the spinal cord; and projects several efferent neurons (such as PVN, DMH, and MPA) to regulate thermoregulation, food intake, sleep, and secretion of humoral mediators (such as glucocorticoids and melatonin) (9) . We used a 30-mg/kg dose of Figure 6 . Effect of compound-A (Comp-A) on gene expression in the hypothalamus of DIO-F344 rats. DIO-F344 rats were orally administered vehicle (Vehi; 0.5% MC solution) and were also administered vehicle or compound-A (30 mg/kg) after 16 hours of fasting or after having been fed ad libitum. At 1 hour after dosing, the rats were anesthetized, and their SCNs were dissected. (a) Brs-3, (b) c-fos, (c) clock, (d) Per1, and (e) Per2 mRNA levels in SCN and (f-h) c-fos mRNA levels in PVN, ARC, and NTS were analyzed by real-time quantitative PCR. The mRNA expression of each gene was normalized to that of cyclophilin. The gray bars correspond to vehicle administration at the fed state, white bars correspond to vehicle administration at the fasting state, and black bars correspond to compound-A administration (30 mg/kg) at the fasting state. The data represent the mean 6 standard deviation for six rats. The statistical significance was determined by using normalized data. *P , 0.05 vs vehicle at the fasting state; #P , 0.05 vs vehicle at the fed state by Tukey multiple comparison test. , and (c and f) nonesterified fatty acid (NEFA) levels were measured by using an autoanalyzer. Plasma corticosterone levels were measured by enzyme-linked immunosorbent assay. The data are expressed as the mean 6 standard deviation (n = 7 each group). *P , 0.05 vs vehicle by the Student t test or Aspin-Welch t test followed by Bonferroni correction for comparing multiple time point vs the control group.
compound-A for evaluation of on gene expression changes in SCN and hypothalamus, peripheral tissues, and plasma parameters in DIO-F344 rats because we hypothesized that energy expenditure enhancement would be associated with them. The maximum efficacy on energy expenditure seemed to be reached at 10 or 30 mg/kg, and repeated dosing of compound-A at 30 mg/kg only showed a significant decrease of body weight in DIO-F344 rats. Because compound-A at 30 mg/kg showed maximum increase of energy expenditure, we thought that the dose of 100 mg/kg might show similar results on increase of energy expenditure; however, we were also afraid of the possibility of increase of off-target events beyond BRS-3. Therefore, we used compound-A at 30 mg/kg on gene expression changes in hypothalamus, peripheral tissue, and plasma parameters in DIO-F344 rats. In future studies, dose-dependent response experiments using less than 30 mg/kg of compound-A would be more informative.
To elucidate the mechanism of the BRS-3 agonist action on circadian rhythms, we measured the expression of circadian rhythm genes. A single administration of compound-A significantly increased the Brs-3 and c-fos mRNA expression in SCN. Moreover, compound-A (30 mg/kg) also significantly increased the mRNA expression of circadian rhythm genes, such as clock, Per1, and Per2, in SCN of DIO-F344 rats, indicating that compound-A stimulated some neuronal action. Thus, one mechanism of the blood pressure increase by the BRS-3 agonist might be associated with sympathetic nervous system activation via SCN stimulation. BRS-3 is also expressed in MPA and DMH of the hypothalamus, which also regulates the sympathetic nervous system (31) . Thus, SCN, MPA, and DMH are considered possible origins of sympathetic nervous system activation by BRS-3 agonist treatment; however, we could not determine the precise mechanism in this study.
Although we did not confirm the brain concentration of compound-A, we have confirmed the brain concentration of the racemate of compound-A, named compound-C. We also showed the plasma and brain concentration of compound-C 1 hour after oral dosing of compound-C at 10 and 30 mg/kg in DIO-F344 rats (Supplemental Table 5 ). As a result, the brain concentration and brain-to-plasma ratio of compound-C by a single treatment at 10 and 30 mg/kg were 0.022 6 0.009 and 0.050 6 0.012 mg/g of brain and 0.066 6 0.010 and 0.102 6 0.018, respectively. Because BRS-3 was mainly expressed in the brain (31, 32) and compound-C existed in the brain, we considered that compound-A could pass the blood-brain barrier and our result would be derived from the direct effect on BRS-3 in the brain. In the future, immunostaining or in situ hybridization with BRS-3 after BRS-3 agonist treatment would be useful for the identification of specific neurons in SCN.
On the other hand, compound-A significantly increased the plasma corticosterone levels and tended to -/Y mice are known to show less anxiety by measurement in an elevated plus maze test and a decreased response to social isolation (25) , and some reports found correlations between circadian rhythm change and anxiety (42) (43) (44) (45) . In this study, because compound-A significantly increased plasma corticosterone levels, which are highly correlated with anxiety, the gene expression changes about circadian rhythm in SCN might be correlated with increase of plasma corticosterone levels and induction of anxiety. Corticosterone elevates blood pressure (46) (47) (48) (49) , and although it is still unclear whether the HPA axis activation by BRS-3 agonists is directly associated with the SCN stimulation, the increase of plasma corticosterone levels might be a mechanism of the transient blood pressure increase effect of BRS-3 agonists.
Corticosterone entrains peripheral clocks, and circulation of glucocorticoids in the blood displays a dynamic circadian rhythm (40) . Corticosterone injection was shown to significantly increase the Per1 mRNA expression in the liver and kidney of rats (50) . Moreover, acute physical stress in mice increased the Per1 mRNA expression in the liver, with an increase of plasma corticosterone levels (51) . Furthermore, the Per1 gene promoter contains tandem glucocorticoid-responsive elements, which trigger the glucocorticoid-mediated Per1 mRNA expression in mouse liver, kidney, and heart (52, 53) .
In addition, expression of some other genes has been reported to correlate with that of peripheral circadian rhythm genes. In the liver, PPARa mRNA expression was reported to be affected by circadian rhythm changes (54, 55) . In WAT, Hsl gene expression has been reported to correlate with plasma corticosterone levels (56) and is affected by a circadian rhythm change by light stimulation (57) . Besides corticosterone, adrenaline increased the Per1 mRNA expression in mouse liver (41) , and the b2-adrenergic receptor agonist procaterol and b3-adrenergic receptor agonist CL316,243 also induced the Per1 mRNA expression in mouse aortic smooth muscle cells (58) . Thus, catecholamines are potential signals from the central master clock that might entrain the peripheral circadian rhythm, including that of the cardiovascular system. The increase of the liver Per1 mRNA levels by compound-A would therefore be mediated by stimulation of sympathetic nervous system via SCN and by the increase of plasma corticosterone levels.
Although we evaluated expression of several peripheral genes after compound-A treatment, only mRNA levels of circadian rhythm-regulated genes, such as PPARa and Hsl, changed, similar to the effects of CL316,243 treatments in DIO-F344 rats. These results suggested that the enhancement of energy expenditure by the BRS-3 agonist might be associated with a change in circadian rhythm gene expression in SCN and might lead to an increase of lipid metabolism in peripheral tissues, with stimulation of the sympathetic nervous system and an increase of plasma corticosterone levels in DIO-F344 rats. Compound-A slightly increased plasma glucose and free fatty acid levels and decreased plasma triglyceride levels. Such effects have been considered to be due to an increase of energy expenditure, with elevation of lipolysis in WAT and plasma corticosterone levels.
In summary, in this study, we developed a specific BRS-3 agonist, compound-A, and demonstrated its antiobesity effects among DIO-F344 rats. We also confirmed that compound-A slightly but significantly increased blood pressure and heart rate in telemeterized SD rats. On the basis of these results, the energy expenditure enhancement by compound-A would be due to circadian rhythm changes in both central and peripheral tissues and stimulation of the sympathetic nervous system. Furthermore, the blood pressure increase by compound-A could be associated with two possible pathways: the sympathetic nervous system stimulation via SCN and the elevation of plasma corticosterone levels through activation of the HPA axis. Because the BRS-3 agonist is considered as a treatment of obesity, even a transient increase in blood pressure is undesirable because this is a cardiovascular risk factor, and the main goal of obesity treatment is the reduction of cardiovascular risk. Hence, lowering the exposure of the brain to the compound by reducing compound lipophilicity may be expected to help avoid these side effects. Recently, such a compound has been generated and showed a reduction in food intake in mice (59) . This might be a novel approach to BRS-3 agonist treatment of obese patients without side effects. Because we evaluated gene expression changes only in central and peripheral tissues, a further deep mechanism analysis is necessary to understand the precise BRS-3 signaling between circadian rhythm and the sympathetic nervous system by using immunostaining or in situ hybridization methods.
In conclusion, we found that a possible mechanism of antiobesity effects and cardiovascular side effects of a BRS-3 agonist in a DIO rodent model would be modulation of circadian rhythm and activation of the HPA axis via SCN, using a selective BRS-3 agonist, compound-A.
